Epizyme Inc (EPZM:NASDAQ) Investor Relations Material

Overview

Epizyme, Inc. is a clinical stage biopharmaceutical company that focuses on developing epigenetic therapies for cancer patients. The company's product platform creates small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases (HMTs). Epizyme's proprietary technology allows it to discover and develop novel drugs targeting these enzymes, which are known to play a critical role in cancer growth and progression. With a pipeline of promising drug candidates, Epizyme is well-positioned to address unmet medical needs in oncology, helping to advance the fight against cancer.

Frequently Asked Questions

What is Epizyme Inc's ticker?

Epizyme Inc's ticker is EPZM

What exchange is Epizyme Inc traded on?

The company's shares trade on the NASDAQ stock exchange

Where are Epizyme Inc's headquarters?

They are based in Cambridge, Massachusetts

How many employees does Epizyme Inc have?

There are 51-200 employees working at Epizyme Inc

What is Epizyme Inc's website?

It is http://www.epizyme.com/

What type of sector is Epizyme Inc?

Epizyme Inc is in the Healthcare sector

What type of industry is Epizyme Inc?

Epizyme Inc is in the Biotechnology industry

Who are Epizyme Inc's peers and competitors?

The following five companies are Epizyme Inc's industry peers:

- BriaCell Therapeutics Corp.

- Seres Therapeutics

- Oncolytics Biotech Inc.

- IVERIC bio

- Aclaris Therapeutics